SWITCHING BIOLOGICS IN PSORIASIS: CHALLENGES AND EXPERIENCE FROM A SMALL TERTIARY HEALTH-CARE CENTER

Milica Bojic Djurovic; Milos Bojic; Ana  Popovic; Mileta Golubovic; Milena  Raznatovic Djurovic

doi:10.5937/sanamed0-48793

Milica Bojic Djurovic Clinical Center of Montenegro, Clinic of Dermatology and Venerology, Podgorica, Montenegro
Milos Bojic Clinical Center of Montenegro, Department of Plastic Surgery, Podgorica, Montenegro
Ana Popovic 1. Clinical Center of Montenegro, Clinic of Dermatology and Venerology, Podgorica, Montenegro; 2. University of Montenegro, Faculty of Medicine, Podgorica, Montenegro
Mileta Golubovic 1. University of Montenegro, Faculty of Medicine, Podgorica, Montenegro; 2. Clinical Center of Montenegro, Department of Pathology, Podgorica, Montenegro
Milena Raznatovic Djurovic 1. Clinical Center of Montenegro, Clinic of Dermatology and Venerology, Podgorica, Montenegro; 2. University of Montenegro, Faculty of Medicine, Podgorica, Montenegro

DOI: https://doi.org/10.5937/sanamed0-48793

Keywords: psoriasis, biologics, switch, primary failure, secondary failure, inefficacy

Abstract

Objective: Psoriasis, a chronic inflammatory skin disease, significantly impacts patients' quality of life. Over the last decade, therapeutic goals have aimed to complete skin clearance and restore normal patient activities, minimizing the disease's impact on social, family, and work activities. Biologics have emerged as a promising solution to achieve better disease control without organ-specific side effects, helping meet these therapeutic goals. However, it was soon noticed that approximately 30% of patients do not sufficiently react to the therapy in the long term, and the need for switching biologics emerges.

Findings: We present our experience with biologic switching over a specific period. Seventeen patients required a switch in biologic agents, with three undergoing a second switch. The cohort predominantly consisted of males (14 out of 17), with an average BMI of 29.81. The primary reasons for switching were secondary failure (loss of initial treatment efficacy), followed by primary failure. Adverse reactions were the least common cause, highlighting the satisfactory safety profile of biologics. One patient underwent dose escalation of secukinumab due to efficacy failure but ultimately ended up switching the biologic.

Conclusion: Biologic agents approved for the treatment of psoriasis showed a favorable safety profile without compromising efficacy. The increasing demand for higher efficacy in psoriasis treatment aims to alleviate the disease's multifaceted impact on patients. It is anticipated that biologic switching, primarily due to inadequate therapeutic response and less frequently due to adverse reactions, will become more prevalent in clinical practice. Literature and our clinical experience suggest that constitutional factors influence treatment success. As new agents and targets emerge, the established standards for biologic switching may require ongoing revision.

Author Biographies

Milica Bojic Djurovic, Clinical Center of Montenegro, Clinic of Dermatology and Venerology, Podgorica, Montenegro

ORCID: 0000-0002-7632-5405

Milos Bojic, Clinical Center of Montenegro, Department of Plastic Surgery, Podgorica, Montenegro

ORCID: 0000-0002-0859-9287

Ana Popovic, 1. Clinical Center of Montenegro, Clinic of Dermatology and Venerology, Podgorica, Montenegro; 2. University of Montenegro, Faculty of Medicine, Podgorica, Montenegro

ORCID: 0009-0001-4306-9089

Milena Raznatovic Djurovic, 1. Clinical Center of Montenegro, Clinic of Dermatology and Venerology, Podgorica, Montenegro; 2. University of Montenegro, Faculty of Medicine, Podgorica, Montenegro

ORCID: 0000-0001-6610-1582

References

Kim J, Bae KN, Son JH, Shin K, Kim HS, Ko HC, et al. Unilateral psoriasis on the left leg and poliomyelitis of the right leg: a case report and review of the etiology. Ann Dermatol. 2023;35(Suppl 1):S93-S96. doi: 10.5021/ad.21.174.

Baloski M, Buklioska ID, Brishkovska-Boshkovski V, Hasan T, Nedeska MN, PrgovaVeljanova B, et al. Deep vein thrombosis and recurrent pulmonary embolism in a patient with thrombophilic mutations and generalized psoriasis: a case report. Sanamed. 2020; 15(2): 183-8.doi:10.24125/sanamed.v15i2.391.

Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21-8. doi: 10.1016/j.clindermatol.2017.09.005.

Đurović MR, Ljaljević A, Djurovic M, Bojic M. The long term ability of heliotherapy in improving the quality of life and alleviating disease activity in patients with psoriasis. International Journal of Scientific Research in Dental and Medical Sciences.2021;3(2):61-5. doi:10.30485/IJSRDMS.2021.278380.1140.

Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65.e19. doi: 10.1016/j.jaad.2018.06.027.

Honda H, Umezawa Y, Kikuchi S, Yanaba K, Fukuchi O, Ito T, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015-9. doi: 10.1111/1346-8138.13860.

Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493-503. doi: 10.1080/17512433.2020.1767590.

Armstrong AW, Patel M, Li C, Garg V, Mandava MR, Wu JJ. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatolog Treat. 2023;34(1):2200870. doi: 10.1080/09546634.2023.2200870.

Shin JO, Shin BS, Bae KN, Shin K, Kim HS, Ko HC, et al. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea. Indian J Dermatol Venereol Leprol. 2023;89(6):928. doi: 10.25259/IJDVL_308_2022.

Ormerod AD. Switching biologics for psoriasis. Br J Dermatol. 2010;163(4):667-9. doi: 10.1111/j.1365-2133.2010.09999.x.

Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655. doi: 10.1183/13993003.00655-2019.

Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. doi: 10.1371/journal.pmed.1002152.

Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5(2):e10. doi: 10.1038/emi.2016.10.

Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest. 2009;119(5):1079-82. doi: 10.1172/jci39143.

Robert M, Miossec P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cell Mol Immunol. 2021;18(7):1644-51. doi: 10.1038/s41423-021-00694-9.

Pirro F, Caldarola G, Chiricozzi A, Burlando M, Mariani M, Parodi A, et al. Impact of Body Mass Index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917-25. doi: 10.1007/s40261-021-01080-z.

Wu MY, Yu CL, Yang SJ, Chi CC. Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis. J Am Acad Dermatol. 2020;82(1):101-9. doi: 10.1016/j.jaad.2019.07.103.